Galapagos creates new warrant plan
May 17 2017 - 4:00PM
Mechelen, Belgium; 17 May 2017, 22.00 CET;
regulated information -- Galapagos NV (Euronext & NASDAQ: GLPG)
announced today that its Board of Directors
created 1,074,500 warrants under new warrant plans for the benefit
of employees, future employees, directors and a consultant of the
Company and its subsidiaries.
On 17 May 2017, the Board of
Directors of Galapagos approved the "Warrant Plan 2017", a warrant
plan intended mainly for certain (future) employees of the Company
and its subsidiaries, and also for directors and an independent
consultant of the Company, and the "Warrant Plan 2017 RMV," a
warrant plan intended for certain employees of the Company's French
subsidiary, Galapagos SASU, within the framework of the authorized
capital. Under these warrant plans, 1,074,500 warrants were
created, subject to acceptances, and offered to the beneficiaries
of the plans.
The offer of warrants to directors
was approved by the Annual Shareholders' Meeting held on
25 April 2017.
The warrants have an exercise term
of eight years as of the date of the offer and have an exercise
price of €80.57 (the average closing price of the share on Euronext
Amsterdam and Brussels during the thirty days preceding the date of
the offer). The warrants are not transferable and can in principle
not be exercised prior to 1 January 2021. Each warrant gives the
right to subscribe to one new Galapagos share. Should the warrants
be exercised, Galapagos will apply for the listing of the resulting
new shares on a regulated stock market. The warrants as such will
not be listed on any stock market.
Galapagos' total share capital
currently amounts to €274,854,440.18; the total number of
securities conferring voting rights is 50,815,648, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
3,369,337, which equals the total number of voting rights that may
result from the exercise of these warrants, and excludes the
1,074,500 warrants of Warrant Plan 2017 and Warrant Plan 2017
RMV, which were created subject to acceptance. Galapagos does not
have any convertible bonds or shares without voting rights
outstanding.
About
Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action. Our
pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical, and
discovery programs in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring
this JAK1-selective inhibitor for inflammatory indications to
patients all over the world. Galapagos is focused on the
development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including
fee-for-service subsidiary Fidelta, has approximately 530
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
CONTACT
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn Fox |
VP IR & Corporate
Communications
+1 781 460 1784 |
Director Communications
+31 6 53 591 999
communications@glpg.com
|
Paul van der Horst
Director IR & Business
Development
+31 6 53 725 199 |
|
ir@glpg.com |
|
Forward-looking statements
This release may contain forward-looking
statements, all of which involve certain risks and uncertainties.
These statements are often, but not always, made through the use of
words or phrases such as "anticipates," "believes," "continues,"
"could," "estimates," "expects," "intends," "may," "plans,"
"seeks," "stands to," "we believe," "will," "we intend," as well as
similar expressions. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors which might
cause the actual results, financial condition and liquidity,
performance or achievements of Galapagos, or industry results, to
be materially different from any historic or future results,
financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In
addition, even if Galapagos' results, performance, financial
condition and liquidity, and the development of the industry in
which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments
in future periods. Among the factors that may result in differences
are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements (including that data from
Galapagos' ongoing clinical research programs may not support
registration or further development of its product candidates due
to safety, efficacy or other reasons), Galapagos' reliance on
collaborations with third parties, and estimating the commercial
potential of Galapagos' product candidates. A further list and
description of these risks, uncertainties and other risks can be
found in Galapagos' Securities and Exchange Commission (SEC)
filings and reports, including in Galapagos'
most recent annual report on form 20-F filed with the SEC and
subsequent filings and reports filed by Galapagos with the SEC.
Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking
statements, unless specifically required by law or
regulation.
GLPG creates new warrant
plan
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Apr 2023 to Apr 2024